Drug
TD 0903
TD 0903: highest development phase Phase 2, developed by Theravance Biopharma. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Theravance Biopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| TD-0903 NCT04402866 | Phase 2 | Acute Lung Injury (ALI) Associated With COVID-19 |
| TD-0903 NCT04350736 | Phase 1 | Acute Lung Injury (ALI) Associated With COVID-19 |
Latest
No recent events.
Follow TD 0903 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.